Polpharma Biologics CEO Discusses Natalizumab Milestone
Q&A With Michael Soldan After CHMP Positive Opinion On Tysabri Biosimilar
In the wake of a positive opinion from the EMA’s CHMP recommending granting a marketing authorization for the firm’s Sandoz-partnered natalizumab biosimilar, Polpharma Biologics CEO Michael Soldan talks to Generics Bulletin about the significance of the development.
